AI Generated Image
Three drugmakers race to prove Lp(a) drugs can prevent heart disease
STAT • • health
Key Points:
- One in five people carry a genetic risk factor called Lp(a) that significantly increases their likelihood of heart disease and heart attacks, which cannot be easily managed through lifestyle changes or current medications.
- Lp(a) levels are primarily determined by genetics, making it a challenging risk factor to address with existing treatments.
- Pharmaceutical companies, including Novartis, are developing experimental drugs targeting Lp(a) and are currently conducting late-stage clinical trials.
- Successfully treating high Lp(a) could fill a major gap in cardiovascular medicine and represents a substantial market opportunity for drugmakers.
